Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 453-458

  Li, Xue Yuan ^a,b   Zhang, Lian Qun ^b   Zhang, Xue Guang ^b   Li, Xin ^b   Ren, Yu Bo ^b   Ma, Xiang Yu ^a   Li, Xin Gang ^a   Wang, Le Xin ^c  

^a SHANDONG UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Astrocytoma; Glioblastoma; Malignancy; mTOR; Signaling pathway

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CHINESE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION;

EID: 85027927262     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0424-1     Document Type: Article

References (16)

1. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430
2. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22 (Pubitemid 47001784)
3. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ (2007) Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26:611-621 (Pubitemid 350115107)
4. Yu K, Shi C, Toral-Barza L et al (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70:621-631
5. Penas-Prado M, Gilbert MR (2007) Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 7:641-661 (Pubitemid 46805561)
6. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of Ras and Akt in neural pro-genitors induces glioblastoma formation in mice. Nat Genet 25:55-57 (Pubitemid 30257036)
7. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66:5618-5623 (Pubitemid 43927113)
8. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657 (Pubitemid 34993700)
9. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC (2005) mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7:356-368 (Pubitemid 40664225)
10. Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. IAR, Lyon, pp 1-253
11. Annovazzi L, Mellai M, Caldera V, Valente G, Valente G, Tessitore L, Schiffer D (2009) mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 29:3087-3094
12. McBride SM, Perez DA, Polley MY (2010) Activation of PI3K/ mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97:33-40
13. Masri J, Bernath A, Martin J et al (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67:11712-11720
14. Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M (2009) Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 35: 731-740
15. Koul N, Sharma V, Dixit D, Ghosh S, Sen E (2010) Bicyclic triterpenoid iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells. BMC Cancer 24(10):328
16. Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Anti-tumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8